Literature DB >> 29622585

Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Anna Axelsson Raja1,2, Hoshang Farhad2, Anne Marie Valente3, John-Paul Couce3,4, John Lynn Jefferies5, Henning Bundgaard1, Kenneth Zahka6, Harry Lever6, Anne M Murphy7, Euan Ashley8, Sharlene M Day9, Mark V Sherrid10, Ling Shi11, David A Bluemke12, Charles E Canter13, Steven D Colan3, Carolyn Y Ho2.   

Abstract

BACKGROUND: Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) is believed to represent dense replacement fibrosis. It is seen in ≈60% of adult patients with hypertrophic cardiomyopathy (HCM). However, the prevalence of LGE in children and adolescents with HCM is not well established. In addition, longitudinal studies describing the development and evolution of LGE in pediatric HCM are lacking. This study assesses the prevalence, progression, and clinical correlations of LGE in children and adolescents with, or genetically predisposed to, HCM.
METHODS: CMR scans from 195 patients ≤21 years of age were analyzed in an observational, retrospective study, including 155 patients with overt HCM and 40 sarcomere mutation carriers without left ventricular (LV) hypertrophy. The extent of LGE was quantified by measuring regions with signal intensity >6 SD above nulled remote myocardium.
RESULTS: Patients were 14.3±4.5 years of age at baseline and 68% were male. LGE was present in 70 (46%) patients with overt HCM (median extent, 3.3%; interquartile range, 0.8-7.1%), but absent in mutation carriers without LV hypertrophy. Thirty-one patients had >1 CMR (median interval between studies, 2.4 years; interquartile range, 1.5-3.2 years). LGE was detected in 13 patients (42%) at baseline and in 16 patients (52%) at follow-up CMR. The median extent of LGE increased by 2.4 g/y (range, 0-13.2 g/y) from 2.9% (interquartile range, 0.8-3.2%) of LV mass to 4.3% (interquartile range, 2.9-6.8%) ( P=0.02). In addition to LGE, LV mass and left atrial volume, indexed to body surface area, and z score for LV mass, as well, increased significantly from first to most recent CMR.
CONCLUSIONS: LGE was present in 46% of children and adolescents with overt HCM, in contrast to ≈60% typically reported in adult HCM. In the subset of patients with serial imaging, statistically significant increases in LGE, LV mass, and left atrial size were detected over 2.5 years, indicating disease progression over time. Further prospective studies are required to confirm these findings and to better understand the clinical implications of LGE in pediatric HCM.

Entities:  

Keywords:  cardiomyopathy, hypertrophic; fibrosis; magnetic resonance imaging; pediatrics; sarcomeres

Mesh:

Substances:

Year:  2018        PMID: 29622585      PMCID: PMC6173664          DOI: 10.1161/CIRCULATIONAHA.117.032966

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

2.  Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Hong-Mi Choi; Kyung-Hee Kim; Joo Myung Lee; Yeonyee E Yoon; Seung-Pyo Lee; Eun-Ah Park; Whal Lee; Yong-Jin Kim; Goo-Yeong Cho; Dae-Won Sohn; Hyung-Kwan Kim
Journal:  Heart       Date:  2015-04-20       Impact factor: 5.994

3.  The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.

Authors:  Carolyn Y Ho; Sharlene M Day; Steven D Colan; Mark W Russell; Jeffrey A Towbin; Mark V Sherrid; Charles E Canter; John L Jefferies; Anne M Murphy; Allison L Cirino; Theodore P Abraham; Matthew Taylor; Luisa Mestroni; David A Bluemke; Petr Jarolim; Ling Shi; Lynn A Sleeper; Christine E Seidman; E John Orav
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

4.  T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.

Authors:  Carolyn Y Ho; Siddique A Abbasi; Tomas G Neilan; Ravi V Shah; Yucheng Chen; Bobak Heydari; Allison L Cirino; Neal K Lakdawala; E John Orav; Arantxa González; Begoña López; Javier Díez; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  Circ Cardiovasc Imaging       Date:  2013-04-02       Impact factor: 7.792

5.  Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy.

Authors:  Jonathan D Windram; Lee N Benson; Andreea Dragelescu; Shi-Joon Yoo; Luc Mertens; Derek Wong; Lars Grosse-Wortmann
Journal:  Congenit Heart Dis       Date:  2015-07-20       Impact factor: 2.007

6.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

7.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

8.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  James C C Moon; Emma Reed; Mary N Sheppard; Andrew G Elkington; Siew Yen Ho; Margaret Burke; Mario Petrou; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.

Authors:  Tevfik F Ismail; Andrew Jabbour; Ankur Gulati; Amy Mallorie; Sadaf Raza; Thomas E Cowling; Bibek Das; Jahanzaib Khwaja; Francisco D Alpendurada; Ricardo Wage; Michael Roughton; William J McKenna; James C Moon; Amanda Varnava; Carl Shakespeare; Martin R Cowie; Stuart A Cook; Perry Elliott; Rory O'Hanlon; Dudley J Pennell; Sanjay K Prasad
Journal:  Heart       Date:  2014-06-24       Impact factor: 5.994

10.  Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype.

Authors:  Bradford Strijack; Vignendra Ariyarajah; Reeni Soni; Davinder S Jassal; Cheryl R Greenberg; Robert McGregor; Andrew Morris
Journal:  J Cardiovasc Magn Reson       Date:  2008-12-16       Impact factor: 5.364

View more
  21 in total

1.  MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.

Authors:  Jing Xu; Baiyan Zhuang; Arlene Sirajuddin; Shuang Li; Jinghan Huang; Gang Yin; Lei Song; Yong Jiang; Shihua Zhao; Minjie Lu
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

2.  Discrepancy Between Pathological Progression and Clinical Stability in a Young Patient With Hypertrophic Cardiomyopathy.

Authors:  Betty Raman; David Wen; Kenneth Chan; Hugh Watkins; Stefan Neubauer; Masliza Mahmod
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

3.  High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young.

Authors:  Anna Wålinder Österberg; Ingegerd Östman-Smith; Robert Jablonowski; Marcus Carlsson; Henrik Green; Cecilia Gunnarsson; Petru Liuba; Eva Fernlund
Journal:  Pediatr Cardiol       Date:  2021-01-30       Impact factor: 1.655

4.  Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model.

Authors:  Anna Axelsson Raja; Hiroko Wakimoto; Daniel M DeLaughter; Daniel Reichart; Joshua Gorham; David A Conner; Mingyue Lun; Clemens K Probst; Norihiko Sakai; Rachel S Knipe; Sydney B Montesi; Barry Shea; Leonard P Adam; Leslie A Leinwand; William Wan; Esther Sue Choi; Eric L Lindberg; Giannino Patone; Michela Noseda; Norbert Hübner; Christine E Seidman; Andrew M Tager; J G Seidman; Carolyn Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-05       Impact factor: 12.779

Review 5.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the Use of Cardiac Magnetic Resonance in Pediatric Congenital and Acquired Heart Disease: Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  Circ Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 8.589

Review 6.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease : Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-21       Impact factor: 6.903

7.  Hypertrophic obstructive cardiomyopathy complicated with acute myocardial infarction and diffuse fibrosis: surgery or not?

Authors:  Yunhong Wang; Xuemei Zhao; Mei Zhai; Yan Huang; Qiong Zhou; Yuhui Zhang; Yi Mao; Jian Zhang
Journal:  BMC Cardiovasc Disord       Date:  2022-04-13       Impact factor: 2.298

Review 8.  Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy.

Authors:  Juan Carlos Brenes; Adelina Doltra; Susanna Prat
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

9.  Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications.

Authors:  Betty Raman; Rina Ariga; Marco Spartera; Sanjay Sivalokanathan; Kenneth Chan; Sairia Dass; Steffen E Petersen; Matthew J Daniels; Jane Francis; Robert Smillie; Adam J Lewandowski; Eric O Ohuma; Christopher Rodgers; Christopher M Kramer; Masliza Mahmod; Hugh Watkins; Stefan Neubauer
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-02-01       Impact factor: 6.875

Review 10.  Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere.

Authors:  Gabrielle Norrish; Ella Field; Juan P Kaski
Journal:  Front Pediatr       Date:  2021-07-02       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.